RC88 is under evaluation for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
RemeGen's Antibody-Drug Conjugate Gets FDA Fast Track Designation for Ovarian Cancer
+ There are no comments
Add yours